Rhumbline Advisers Day One Biopharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q4 2024
A detailed history of Rhumbline Advisers transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 75,553 shares of DAWN stock, worth $890,014. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75,553
Previous 77,300
2.26%
Holding current value
$890,014
Previous $1.08 Million
11.06%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding DAWN
# of Institutions
176Shares Held
77.8MCall Options Held
139KPut Options Held
253K-
Atlas Venture Life Science Advisors, LLC6.43MShares$75.7 Million13.44% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.85MShares$68.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.76MShares$67.8 Million1.18% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$57.4 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$53.4 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $865M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...